# US 2012/0083520 A1 · Ghrelin binding nucleic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083520 A1
- Document ID: US20120083520A1
- Status: Published application
- Kind: A1
- Application number: 12/776,377
- Filed: 2010-05-08
- Published: 2012-04-05
- Earliest claimed: 2002-08-01
- Assignees: NOXXON Pharma AG
- Inventors: Steffen Helmling; Dirk Eulberg; Christian Maasch; Sven Klussmann
- Web page: https://patentgrep.com/patent/US20120083520A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/16: Aptamers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to a nucleic acid antagonist of ghrelin.

## Claims

### Claim 1

An antagonist of ghrelin, wherein the antagonist is a nucleic acid which specifically binds ghrelin.

### Claim 2 (depends on 1)

An antagonist of the GHSR 1a receptor system, wherein the antagonist is the nucleic acid of claim 1.

### Claim 3 (depends on 1)

The antagonist according to claim 1, wherein said nucleic acid comprises at least one L-nucleotide.

### Claim 4 (depends on 3)

The antagonist of claim 3, wherein the antagonist is an L-nucleic acid.

### Claim 5 (depends on 1)

The antagonist of claim 1, wherein said ghrelin is L-ghrelin.

### Claim 6 (depends on 1)

The antagonist of claim 1, wherein said nucleic acid comprises any one of SEQ ID NO:7 to SEQ ID NO:125.

### Claim 7 (depends on 1)

The antagonist of claim 1, wherein the nucleic acid is selected from the group consisting of DNA, RNA and combinations thereof.

### Claim 8 (depends on 1)

The antagonist of claim 1, wherein said nucleic acid has a Kd less than 1 μM.

### Claim 9 (depends on 8)

The antagonist of claim 8, wherein said nucleic acid has a Kd less than 0.25 μM.

### Claim 10 (depends on 9)

The antagonist of claim 9, wherein said nucleic acid has a Kd less than 0.1 μM.

### Claim 11 (depends on 10)

The antagonist of claim 10, wherein said nucleic acid has a Kd less than 0.01 μM.

### Claim 12 (depends on 1)

The antagonist of claim 1, wherein said nucleic acid has a Kd more than 100 nM.

### Claim 13 (depends on 12)

The antagonist of claim 12, wherein said nucleic acid has a Kd more than 10 nM.

### Claim 14 (depends on 13)

The antagonist of claim 13, wherein said nucleic acid has a Kd more than 1 nM.

### Claim 15 (depends on 1)

The antagonist of claim 1, wherein said nucleic acid has a Kd more than 0.05 nM.

### Claim 16 (depends on 1)

The antagonist of claim 1, wherein the nucleic acid comprises 15 to 150 nucleotides.

### Claim 17 (depends on 16)

The antagonist of claim 16, wherein the nucleic acid comprises 20 to 60 nucleotides.

### Claim 18 (depends on 17)

The antagonist of claim 17, wherein said nucleic acid comprises 30 to 50 nucleotides.

### Claim 19 (depends on 1)

A method for making the nucleic acid of claim 1, comprising the following steps:
a) generating a heterogeneous population of nucleic acids;
b) contacting the population of step a) with a ghrelin;
c) separating the nucleic acid(s) not interacting with said ghrelin;
d) optionally separating the nucleic acid(s) interacting with said ghrelin; and
e) optionally sequencing the nucleic acid(s) interacting with said ghrelin.

### Claim 20 (depends on 19)

The method according to claim 19, further comprising subsequent to step c), step ca) amplifying nucleic acid(s) interacting with ghrelin.

### Claim 21 (depends on 19)

The method according to claim 19, wherein steps b) to d) are repeated.

### Claim 22 (depends on 4)

A method for making the L-nucleic acid of claim 4 comprising:
a) generating a heterogeneous population of D-nucleic acids;
b) contacting the population of step a) with a D-ghrelin;
c) separating the D-nucleic acid not interacting with said D-ghrelin;
d) sequencing the D-nucleic acid interacting with said D-ghrelin; and
e) synthesising the L-nucleic acid sequence(s) which is/are identical to the sequence of the D-nucleic acid(s) obtained in step d).

### Claim 23 (depends on 22)

The method according to claim 22, further comprising subsequent to step c):
ca) amplifying the D-nucleic acid interacting with D-ghrelin.

### Claim 24 (depends on 22)

The method according to claim 22, characterised in that steps b) to e) are repeated.

### Claim 25 (depends on 1)

The antagonist of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1)

A complex comprising ghrelin and the antagonist of claim 1.

### Claim 27 (depends on 26)

The complex claim 26, which is crystalline.

### Claim 28 (depends on 1)

A method for identifying a ghrelin comprising exposing a sample suspected of containing a ghrelin to the antagonist of claim 1 and detecting complexes of said ghrelin and said antagonist.

### Claim 29 (depends on 1)

A method for screening for the antagonist of claim 1 comprising:
providing a candidate ghrelin antagonist,
providing the antagonist of claim 1,
providing a test system providing a signal in the presence of a ghrelin antagonist, and
determining whether the candidate ghrelin antagonist is a ghrelin antagonist.
